



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Brief communication

Tuberculosis incidence among people living with HIV/AIDS with virological failure of antiretroviral therapy in Salvador, Bahia, Brazil



Monaliza Cardozo Rebouças^{a,*}, Márcio Oliveira da Silva^a, Tatiana Haguihara^a, Carlos Brites^b, Eduardo Martins Netto^b

^a Secretaria de Saúde do Estado da Bahia (SESAB), Centro Especializado em Diagnóstico, Assistência e Pesquisa (CEDAP), Salvador, BA, Brazil

^b Universidade Federal da Bahia (UFBA), Programa de Pós-graduação em Medicina e Saúde (PPGMS), Salvador, BA, Brazil

ARTICLE INFO

Article history:

Received 15 March 2017

Accepted 14 May 2017

Available online 16 June 2017

Keywords:

Tuberculosis

Virological failure

HIV infection

ABSTRACT

Antiretroviral therapy for HIV has led to increased survival of HIV-infected patients. However, tuberculosis remains the leading opportunistic infection and cause of death among people living with HIV/AIDS. Tuberculosis has been shown to be a good predictor of virological failure in this group. This study aimed to evaluate the incidence of tuberculosis and its consequences among individuals diagnosed with virological failure of HIV. This was a retrospective cohort study involving people living with HIV/AIDS being followed-up in an AIDS reference center in Salvador, Bahia, Brazil. Individuals older than 18 years with HIV infection on antiretroviral therapy for at least six months, diagnosed with virological failure (HIV-RNA greater than or equal to 1000 copies/mL), from January to December 2013 were included. Tuberculosis was diagnosed according to the criteria of the Brazilian Society of Pneumology. Fourteen out of 165 (8.5%) patients developed tuberculosis within two years of follow-up (incidence density = 4.1 patient-years). Death was directly related to tuberculosis in 6/14 (42.9%). A high incidence and tuberculosis-related mortality was observed among patients with virological failure. Diagnosis of and prophylaxis for tuberculosis in high-incidence countries such as Brazil is critical to decrease morbidity and mortality in people living with HIV/AIDS.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The introduction of highly active antiretroviral therapy (HAART) has led to increased survival among HIV-infected patients and improved the quality of life of people living with HIV/AIDS (PLWHA).¹ However, tuberculosis (TB) remains the

most common opportunistic infection and a leading cause of death among patients with HIV, particularly in sub-Saharan African and Asian countries, where it is highly prevalent.^{2,3} Worldwide, it is estimated that there were 9.0 million new TB

* Corresponding author.

E-mail address: monaenf@hotmail.com (M.C. Rebouças).

<http://dx.doi.org/10.1016/j.bjid.2017.05.005>

1413-8670/© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

cases in 2013, 13% of whom were PLWHA.² In Brazil, 73,000 new TB cases were detected, and 4577 deaths occurred in 2013.⁴ In Bahia, a northeastern state of Brazil, the incidence of TB is decreasing slowly, and it is the state with the fourth largest number of TB cases in Brazil.⁵

An estimated 36.7 million people are living with HIV worldwide and of these, 17 million are using antiretroviral therapy (ART).¹ In Brazil, it is estimated that approximately 798,000 people were living with HIV in 2014, a prevalence of 0.39%. Of these, approximately 405,000 PLWHA were on ART, and 356,000 (88%) of them presented with viral suppression at least six months after initiation of antiretroviral therapy.⁶

The risk of TB in HIV-infected patients and the impact of TB diagnosis on disease progression in HIV-infected patients have been well described in Africa.^{3,7} It is known that PLWHA once infected with *Mycobacterium tuberculosis* have a risk of developing overt TB of approximately 5–10% per annum, higher than for the general population⁸; moreover, TB may occur at any stage of HIV infection. The management of HIV infections in persons with TB is complicated by several factors, including drug interaction, overlapping drug toxicities, exacerbation of side effects, concerns about adherence, and immune reconstitution inflammatory syndrome (IRIS).⁹ Some studies suggest that virological failure is more likely to ensue in patients diagnosed with TB after starting ART therapy develop, suggesting that it is a result of the above-mentioned factors associated with double infection.^{10–12}

Although the success rates of ART are considered high, other factors may be associated with the occurrence of virological failure. Singh et al.¹² and Tran et al.¹³ pointed to TB as a predictor of virological failure, as well as the most frequent opportunistic infection among individuals who change ARV regimens.

Currently, early initiation of ART is recommended, but this strategy can potentially increase the risk of HIV resistance.^{5,14} This underscores the importance of virological monitoring in the clinical treatment routine. Early recognition of virological failure and TB control is critical to minimize the consequences of partial or incomplete viral suppression. Few studies have shown the occurrence of TB associated with virological failure. This study aimed to evaluate the incidence of TB and its consequences among individuals diagnosed with virological failure of HIV.

This is a retrospective cohort study involving PLWHA followed in the State Center Specialized in Diagnosis, Care, and Research (CEDAP), the largest reference center for treatment of PLWHA in Salvador, Bahia, Brazil, where 3200 HIV/AIDS patients are under therapy. We included patients over 18 years of age, with a confirmed diagnosis of HIV infection, who were diagnosed with virological failure in the period from January to December 2013. These subjects were followed until December 2015. Sociodemographic, behavioral, clinical, and laboratory data were obtained from clinical records, pharmacy reports of ART and TB drugs, and in the following databases: (a) Internal Registration CEDAP Laboratory data – CompLab; (b) Logistics Management System Drugs – SICLOM; (c) System Laboratory Tests Control of the National Network of Lymphocyte Count CD4/CD8 and viral load – SISCEL; and (d) Brazilian Information System on Mortality – SIM.

Virological failure was defined as detectable HIV RNA above 1000 copies/mL (Abbot molecular, Illinois, USA) in individuals on ART for at least six months. TB diagnosis was assessed by identification of *M. tuberculosis* in cultures or acid-fast smears in sputum or other tissues, compatible histological findings from tissue biopsies, or compatible clinical features, according to the Brazilian Pneumology Society.¹⁵ Information on death was obtained from SIM. The survival time was calculated as the time elapsed between the diagnosis of virological failure and date of death or date of last visit to the Center.

Statistical analyses included χ^2 and Fisher's exact tests for comparisons of seroprevalence rates and a two-tailed Mann–Whitney *U* test for comparisons of sociodemographic indicators and laboratory test results between individuals with or without a diagnosis of TB. Statistical analyses were performed with SPSS V18. Results were considered statistically significant at $p < 0.05$. Survival analysis was performed using Cox backward stepwise regression analysis with the variables associated or near association (less than eight years of education, less than 200 cells/mm³ of CD4 at failure, CMV retinitis or CNS toxoplasmosis, presence of comorbidities), prediction of death between groups (with or without a diagnosis of TB). This study was approved by the Research Ethics Committee of the Health Department of the Bahia's State (SESAB), number 452782.

We identified 165 patients with HIV infection with virological failure in 2013 (Fig. 1A). TB incidence was 8.5% (14 cases) within the two years of follow-up (incidence density = 4.1 cases in 100 patient-years). Among these 165 patients, 41 (32.7%) had a history of TB infection prior to virological failure. Of these, 16 (9.7%) patients already had active TB at the time of HIV diagnosis and started ART an average of 428.6 days after diagnosis (median 183 days). Seven (4.2%) patients postponed the initiation of ART because of TB diagnosis an average of 1300 days after the diagnosis of HIV (median = 1038 days). Ten (18.9%) of these patients developed TB while being treated with ART but before HIV virological failure.

Of the 165 patients included, 19 (11.5%) died. There were six deaths directly related to TB/HIV co-infection (42.9%), with a mortality rate of 1.7 in 100 patient-years. Poorer survival was observed in patients who developed TB during follow-up and TB related mortality was high ($p < 0.01$) (Fig. 1B).

In our cohort TB was more incident in males (71.4%), self-reported blacks (57.1%), heterosexuals (64.3%), and those with less than four years of education (71.4%). The most frequent age group was 30–39 years (35.7%) with a mean age of 36.9 years (range: 18–67 years). Less than eight years of education, CD4 T-cell count below 200 cells/mm³, and presence of clinical comorbidities were associated with the incidence of TB in these patients with virological failure (Table 1). The median CD4 count at the moment of virological failure was 123 cells/mm³ (± 204), lower than that at diagnosis (152.5 cells/mm³; $p < 0.01$). In the last follow-up visit, only 14.3% had a viral load of < 50 HIV RNA copies/mL. High median viral load and low CD4 count were associated with increased incidence of TB and lower survival ($p < 0.01$) as shown in Fig. 1B, C and D. After multivariate analysis, all variables previously associated in the univariate analysis remained statistically associated with the occurrence of TB.

Download English Version:

<https://daneshyari.com/en/article/5665602>

Download Persian Version:

<https://daneshyari.com/article/5665602>

[Daneshyari.com](https://daneshyari.com)